# Charles River (CRL) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/CRL
## Company Profile
- Ticker: CRL
- Exchange: NYSE
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 265.51 USD
- Market cap: 8419237526.7 USD
- Last updated: 2026-08-06
## Business Overview
### Preclinical Research Services
Charles River Laboratories provides products and outsourced services used by pharmaceutical, biotechnology, academic and government researchers across early drug development.
### Research Models and Services
The company supplies research models and related services used in basic research, target validation and preclinical studies. It also provides safety-assessment and discovery services.
### Manufacturing Solutions
Charles River supports biologic testing, microbial solutions and other quality-control activities used in pharmaceutical manufacturing. Following divestitures, the company is refocusing on its core research and preclinical portfolio.
## Why The Stock Is Moving

Following the latest company update, “Charles River Laboratories Announces Second-Quarter 2026 Results”, CRL closed up 11.4% at $260.72 on Aug 5, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- Charles River’s catalysts are discovery-spend recovery, model-and-services demand, and any improvement in biopharma outsourcing. This matters because it helps show whether the company can turn its current footprint into a cleaner earnings profile. Better execution here can matter even before a new product or trial headline lands.

## Recent News
- 2026-08-05 11:00 EST — [Charles River Laboratories Announces Second-Quarter 2026 Results](https://biopharmsignal.com/news/CRL/charles-river-laboratories-announces-second-quarter-2026-results-9fc8eef8) — Source: Charles River
- 2026-07-15 12:00 EST — [Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/CRL/charles-river-laboratories-schedules-second-quarter-2026-earnings-release-and-co-1ac856d9) — Source: Charles River
- 2026-07-13 12:00 EST — [Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches](https://biopharmsignal.com/news/CRL/charles-river-provides-ngs-services-to-arovella-therapeutics-accelerating-progre-ea8e3539) — Source: Charles River
- 2026-06-18 12:00 EST — [Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise](https://biopharmsignal.com/news/CRL/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-f5af9c6a) — Source: Charles River
- 2026-06-01 12:00 EST — [Charles River Laboratories to Present at William Blair and Jefferies Conferences](https://biopharmsignal.com/news/CRL/charles-river-laboratories-to-present-at-william-blair-and-jefferies-conferences) — Source: Charles River